The presence of hypoxic cells within tumors and the implications of this situation for cancer therapy were first noted over 50 years ago by Thomlinson and Gray. Since that time, a plethora of studies have confirmed the existence of hypoxic cells within a variety of tumor types as well as the prognostic importance of hypoxia in the clinical management of human cancers. The role of hypoxia as a key determinant of outcome for human cancers has encouraged efforts to noninvasively detect and localize regions of poor oxygenation in tumors. In this review, we will summarize existing and developing techniques for imaging tumoral hypoxia.
Biology of Tumor Hypoxia
Most tumors possess (1) lower oxygen levels than their corresponding tissue of origin, (2) significant intra- and intertumoral variation in oxygen concentrations, and (3) lower oxygenation at the time of recurrence than the corresponding primary tumor.[2,3] Hypoxic tumors are more refractory to therapy and are associated with an aggressive tumor phenotype. For example, the "oxygen effect" has been well studied and dictates that the radiation dose required to kill a given fraction of cells in a cell population fully deprived of oxygen is 2.5 to 3 times greater than that required to achieve an equal amount of cell kill in an aerobic cell population.[4-6] Hypoxia-induced resistance to chemotherapy including cyclophosphamide, carboplatin, and doxorubicin,[7,8] have also been noted. Tumor hypoxia has been associated in both laboratory and clinical studies with a more aggressive neoplastic phenotype as well as with increased potential for invasion, growth, and metastasis.[9-16]
A cascade of alterations in cellular gene expression are induced by the absence of oxygen. A central player in the ability of tumor cells to adapt to a low oxygen environment is the hypoxia-inducible factor 1 (HIF-1). HIF-1 is a heterodimeric protein consisting of an oxygen-regulated alpha subunit and a constitutively expressed beta subunit. In the presence of oxygen, a family of prolyl hydroxylases are activated and hydroxylate two proline residues of HIF-1-alpha (P402 and P564).[18-20] Following hydroxylation, HIF-1-alpha is then further modified by the addition of ubiquitin molecules through association with a complex consisting of the von-Hippel Lindau (VHL) protein and elongins B and C, after which the protein is rapidly degraded by the proteasome. In cells with wild-type expression of all components of this pathway, HIF-1-alpha therefore only persists under hypoxic conditions where the oxygen-dependent degradation pathway is inactive due to inhibition of the prolyl hydroxylases that require molecular oxygen. In these situations, HIF-1-alpha combines with HIF-1-beta to generate the composite transcription factor HIF-1, and selectively activate transcription of genes bearing promoters containing HIF-1-binding hypoxia-response elements (HREs).
A number of clinical studies have shown that increased expression of HIF-1-alpha is a significant negative prognostic indicator for many types of cancer, including brain,[22,23] breast,[24-26] cervix,[27-29] esophagus, head and neck,[31,32] and uterus. These observations have encouraged the development of a variety of anti-HIF-1 cancer therapeutics.[34,35] It has furthermore been observed that HIF-1-alpha can be found in oxic as well as hypoxic conditions in many types of tumor cells. This finding provides evidence of oxygen-independent regulation of HIF-1 in tumor cells, a process that is partly mediated by loss and/or gain of function mutations in a number of genes relating to the degradation pathway described above, such as VHL.[34,35]
A variety of growth factors including insulin and insulin-like growth factor 1 (IGF-1) have also been shown to stimulate oxygen-independent accumulation of HIF-1 through the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway.[37-39] Overexpression of HIF-1 and its downstream genes, including vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT-1), lysyl oxidase (LOX), and carbonic anhydrase IX (CA IX), appears to be at least partly responsible for the phenotype of increased aggressiveness, invasion, metastasis, and resistance to therapy associated with hypoxic tumor cells.[35,40]
Gatenby and Gillies have speculated that hypoxic conditions in premalignant lesions may select for tumor cells overexpressing HIF-1 because of the survival advantage it provides. This could produce adult tumors with elevated HIF-1 levels under both oxic and hypoxic conditions that would therefore constitutively exhibit an aggressive phenotype. Two recent experimental studies have suggested that the absence of HIF-1-alpha confers therapeutic sensitivity independent of tissue oxygen levels, indicating that HIF-1-alpha is an effector and not merely a surrogate of hypoxia-mediated therapeutic resistance.[42,43] Thus, HIF-1 and hypoxia represent two related but independently significant aspects of cancer biology. Correspondingly, imaging methods and therapies targeting HIF-1 and/or HIF-1-alpha in tumors, while not necessarily specific to oxygenation status, may nonetheless be directed toward neoplastic cells with a more malignant phenotype.
Measuring Tumoral Oxygenation
A variety of techniques have been advanced for the identification and quantification of tumoral hypoxia. A compilation of these methods is given in Table 1. The past gold standard for measurement of oxygen levels in tumors is the Eppendorff needle electrode, which applies a voltage to cause the reduction of molecular oxygen to hydroxide. The current produced is then measured and related to the concentration of oxygen within the measurement volume. Alternative probe-based oxygen measurement strategies have been developed, including systems based on oxygen-sensitive fluorophores such as the OxyLite.
In addition, immunohistochemical methods have been applied to detect markers of hypoxia in biopsy samples taken from cancer patients. These markers include both exogenous, systemically delivered probes that are administered to a patient, localize in hypoxic regions, and are detected by antibody techniques in tissue specimens (pimonidazole,[46,47] EF5), as well as endogenous proteins that are overexpressed under hypoxic conditions (HIF-1-alpha, CA IX). These methods bear restrictions to their applicability and utility because of their invasive nature, the possibility of sampling error in relating discrete and/or microscopic observations to a macroscopic, potentially heterogenous tumor, and the inability to perform serial measurements needed to assess changes in oxygenation during treatment.
The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955.
2. Höckel M, Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276, 2001.
3. Brown JM, Wilson WR: Exploiting tumor hypoxia in cancer treatment. Nat Rev Canc 4:437-447, 2004.
4. Read J: Mode of action of x-ray doses given with different oxygen concentrations. Br J Radiol 25:651-661, 1952.
5. Gray LH, Conger AD, Ebert M, et al: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648, 1953.
6. Wright EA, Howard-Flanders P: The influence of oxygen on the radiosensitivity of mammalian tissues. Acta Radiol 48:26-32, 1957.
7. Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73-81, 1981.
8. Teicher BA, Holden SA, al-Achi A, et al: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaII murine fibrosarcoma. Cancer Res 50:3339-3344, 1990.
9. Young SD, Marshall RS, Hill RP: Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 85:9533-9537, 1988.
10. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943, 1996.
11. Höckel M, Schlenger K, Aral B, et al: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509-4915, 1996.
12. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997.
13. Cuvier C, Jang A, Hill RP: Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 15:19-25, 1997.
14. Sundfor K, Lyng H, Rofstad EK: Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 78:822-827, 1998.
15. Höckel M, Schlenger K, Höckel S, et al: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59:4525-4528, 1999.
16. Walenta S, Wetterling M, Lehrke M, et al: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60:916-921, 2000.
17. Wang GL, Jiang BH, Rue EA, et al: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92:5510-5514, 1995.
18. Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340, 2001.
19. Schofield CJ, Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cel Biol 5:343-354, 2004.
20. Chan DA, Sutphin PD, Yen SE, et al: Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25:6415-6426, 2005.
21. Kim W, Kaelin WG: The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr Opin Genet Dev 13:55-60, 2003.
22. Birner P, Gatterbauer B, Oberhuber G, et al: Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and neoangiogenesis. Cancer 92:165-171, 2001.
23. Korkolopoulou P, Patsouris E, Konstantinidou AE, et al: Hypoxia-inducible factor 1 alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30:267-278, 2004.
24. Schindl M, Schoppmann SF, Samonigg H, et al: Overexpression of hypoxia-inducible factor 1 alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831-1837, 2002.
25. Bos R, van der Groep P, Greijer AE, et al: Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573-1581, 2003.
26. Dales JP, Garcia S, Meunier-Carpentier S, et al: Overexpression of hypoxia-inducible factor HIF-1 alpha predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Cancer 116:734-739, 2005.
27. Birner P, Schindl M, Obermair A, et al: Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage cervical cancer. Cancer Res 60:4693-4696, 2000.
28. Burri P, Djonov V, Aebersold DM, et al: Significant correlation of hypoxia-inducible factor-1 alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56:494-501, 2003.
29. Ishikawa H, Sakurai H, Hasegawa M, et al: Expression of hypoxia-inducible factor 1 alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 60:513-521, 2004.
30. Kimura S, Kitadai Y, Tanaka S, et al: Expression of hypoxia-inducible factor (HIF)-1 alpha is associated with vascular endothelial growth factor expression and tumor angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer 40:1904-1912, 2004.
31. Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911-2916, 2001.
32. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202, 2002.
33. Sivridis E, Giatromanolaki A, Gatter KC, et al: Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055-1063, 2002.
34. Giaccia A, Siim BG, Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2:803-811, 2003.
35. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732, 2003.
36. Semenza GL: Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 41:79-83, 2002.
37. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545, 2000.
38. Fukuda R, Hirota K, Fan F, et al: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-38211, 2002.
39. Stiehl DP, Jelkmann W, Wenger RH, et al: Normoxic induction of the hypoxia-inducible factor-1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 512:157-162, 2002.
40. Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226, 2006.
41. Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899, 2004.
42. Unruh A, Ressel A, Mohamed HG, et al: The hypoxia-inducible factor-1alpha is a negative factor for tumor therapy. Oncogene 22:3213-3220, 2003.
43. Williams KJ, Telfer BA, Xenaki D, et al: Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75:89-98, 2005.
44. Kallinowski F, Zander R, Höckel M, et al: Tumor tissue oxygenation as evaluated by computerized pO2-histography. Int J Radiat Oncol Biol Phys 19:953-961, 1990.
45. Griffiths JR, Robinson SP: The OxyLite: A fibre-optic oxygen sensor. Br J Radiol 72:627-630, 1999.
46. Raleigh JA, Dewhirst MW, Thrall DE: Measuring tumor hypoxia. Semin Radiat Oncol 6:37-45, 1996.
47. Kennedy AS, Raleigh JA, Perez GM, et al: Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 37:897-905, 1997.
48. Koch CJ, Evans SM, Lord EM: Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 72:869-874, 1995.
49. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835, 1999.
50. Ivanov S, Liao S, Ivanova A, et al: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919, 2001.
51. Hull EL, Conover DL, Foster TH: Carbogen-induced changes in rat mammary tumour oxygenation reported by near infrared spectroscopy. Br J Cancer 79:1709-1716, 1999.
52. Benaron DA, Parachikov IH, Cheong WF, et al: Design of a visible-light spectroscopy clinical tissue oximeter. J Biomed Opt 10:44005, 2005.
53. Bluestone AY, Abdoulaev G, Schmitz CH, et al: Three-dimensional optical tomography of hemodynamics in the human head. Opt Expr 9:272-286, 2001.
54. Baudelet C, Gallez B: How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn Reson Med 48:980-986, 2002.
55. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, et al: Changes in oxygenation of intracranial tumors with carbogen: A BOLD MRI and EPR oximetry study. J Magn Reson Imaging 16:511-521, 2002.
56. Le D, Mason RP, Hunjan S, et al: Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. Magn Reson Imaging 15:971-981, 1997.
57. Hunjan S, Mason RP, Constantinescu A, et al: Regional tumor oximetry: 19F NMR spectroscopy of hexafluorobenzene. Int J Radiat Oncol Biol Phys 41:161-171, 1998.
58. Rasey JS, Koh WJ, Grierson JR, et al: Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 17:985-991, 1989.
59. Rajendran JG, Mankoff DA, O'Sullivan F, et al: Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245-2252, 2004.
60. Sorger D, Patt M, Kumar P, et al: [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30:317-326, 2003.
61. Reischl G, Ehrlichmann W, Bieg C, et al: Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot 62:897-901, 2005.
62. Ziemer LS, Evans SM, Kachur AV, et al: Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med 30:259-266, 2003.
63. Lewis JS, McCarthy DW, McCarthy TJ, et al: Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40:177-183, 1999.
64. Dehdashti F, Mintun MA, Lewis JS, et al: In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30:844-850, 2003.
65. Zanzonico P, O'Donoghue J, Chapman JD, et al: Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 31:117-128, 2004.
66. Cui C, Wani MA, Wight D, et al: Reporter genes in transgenic mice. Transgenic Res 3:182-194, 1994.
67. Hadjantonakis AK, Nagy A: The color of mice: In the light of GFP-variant reporters. Histochem Cell Biol 115:49-58, 2001.
68. Yang M, Baranov E, Jiang P, et al: Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A 97:1206-1211, 2000.
69. Contag CH, Spilman SD, Contag PR, et al: Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol 66:523-531, 1997.
70. Contag PR, Olomu IN, Stevenson DK, et al: Bioluminescent indicators in living mammals. Nat Med 4:245-247, 1998.
71. Bhaumik S, Gambhir SS: Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A 99:377-382, 2002.
72. Gambhir SS, Bauer E, Black ME, et al: A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A 97:2785-2790, 2000.
73. Tjuvajev JG, Doubrovin M, Akhurst T, et al: Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 43:1072-1083, 2002.
74. Min JJ, Iyer M, Gambhir SS: Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: Adenoviral infection vs stable transfection. Eur J Nucl Med Mol Imaging 30:1547-1560, 2003.
75. Serganova I, Doubrovin M, Vider J, et al: Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 64:6101-6108, 2004.
76. Wen B, Burgman P, Zanzonico P, et al: A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 31:1530-1538, 2004.
77. Liu J, Qu R, Ogura M, et al: Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo) 46:93-102, 2005.
78. Harada H, Kizaka-Kondoh S, Hiraoka M: Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4:182-193, 2005.
79. Safran M, Kim WY, O'Connell F, et al: Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 103:105-110, 2006.
80. Cecic I, Chan DA, Sutphin PD, et al: Triple fusion reporter protein expression and activity under hypoxic conditions (abstract 171). Proceedings of the Annual Conference of the Academy of Molecular Imaging; Orlando, Florida; 2005; p 125.
81. Supuran CT, Scozzafava A, Casini A: Carbonic anhydrase inhibitors. Med Res Rev 23:146-189, 2002.
82. Hilvo M, Rafajova M, Pastoreková S, et al: Expression of carbonic anhydrase IX in mouse tissues. J Histochem Cytochem 52:1313-1322, 2004.
83. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399-3403, 2001.
84. Loncaster JA, Harris AL, Davidson SE, et al: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394-6399, 2001.
85. Giatromanolaki A, Koukourakis MI, Sivridis E, et al: Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61:7992-7998, 2001.
86. Hui EP, Chan ATC, Pezzella F, et al: Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595-2604, 2002.
87. Span PN, Bussink J, Manders P, et al: Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 89:271-276, 2003.
88. Kim SJ, Rabbani ZN, Vollmer RT, et al: Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10:7925-7933, 2004.
89. Haapasalo JA, Nordfors KM, Hilvo M, et al: Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473-477, 2006.
90. Robertson N, Potter C, Harris AL: Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64:6160-6165, 2004.
91. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38:489-494, 1986.
92. Pastoreková S, Zavadova Z, Kostal M, et al: A novel quasi-viral agent, MaTu, is a two-component system. Virology 187:620-626, 1992.
93. Velders MP, Litvinov SV, Warnaar SO, et al: New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 54:1753-1759, 1994.
94. Zat'ovicová M, Tarábková K, Svastová E, et al: Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods 282:117-134, 2003.
95. Brouwers A, Verel I, Van Eerd J, et al: PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 19:155-163, 2004.
96. Divgi CR, O'Donoghue JA, Welt S, et al: Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45:1412-1421, 2004.
97. Brouwers AH, Dörr U, Lang O, et al: 131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: A comparative study. Nucl Med Commun 23:229-236, 2002.
98. Brouwers AH, Buijs WCAM, Mulders PFA, et al: Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: Dosimetric analysis and immunologic response. Clin Cancer Res 11:7178s-7186s, 2005.
99. Brouwers A, Mulders P, Oosterwijk E, et al: Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: Preclinical and clinical pilot studies. Cancer Biother Radiopharm 19:466-477, 2004.
100. Chrastina A, Závada J, Parkkila S, et al: Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 105:873-881, 2003.
101. Abbate F, Supuran CT, Scozzafava A, et al: Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: Role of hydrogen-bonding networks in ligand binding and drug design. J Med Chem 45:3583-3587, 2002.
102. Winum J, Vullo D, Casini A, et al: Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 46:2197-2204, 2003.
103. Vullo D, Scozzafava A, Pastoreková S, et al: Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg Med Chem Lett 14:2351-2356, 2004.
104. Cecchi A, Hulikova A, Pastorek J, et al: Carbonic anhydrase inhibitors. design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 48:4834-4841, 2005.
105. Dehdashti F, Grigsby PW, Mintun MA, et al: Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55:1233-1238, 2003.
106. Rischin D, Hicks RJ, Fisher R, et al: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098-2104, 2006.
107. Chao KS, Bosch WR, Mutic S, et al: A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49:1171-1182, 2001.
108. Paulino AC, Koshy M, Howell R, et al: Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 61:1385-1392,
109. Rajendran JG, Hendrickson KRG, Spence AM, et al: Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 33:S44-S53, 2006.
110. Höckel M, Schlenger K, Knoop C, et al: Oxygenation of carcinomas of the uterine cervix: Evaluation by computerized O2 tension measurements. Cancer Res 51:6098-6102, 1991.
111. Vaupel P, Schlenger K, Knoop C, et al: Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51:3316-3322, 1991.
112. Collingridge DR, Young WK, Vojnovic B, et al: Measurement of tumor oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res 147:329-334, 1997.
113. Swartz HM, Bacic G, Friedman B, et al: Measurements of pO2 in vivo, including human subjects, by electron paramagnetic resonance. Adv Exp Med Biol 361:119-128, 1994.